Pain News and Research

Latest Pain News and Research

Diabetic women more likely to report low overall sexual satisfaction

Women with diabetes are just as likely to be interested in, and engage in, sexual activity as non-diabetic women, but they are much more likely to report low overall sexual satisfaction, according to a UCSF study.

26 Jul 2012

Studies look at surgical site infections and hyperglycemia

Two recent studies in the July issues of the Journal of Bone and Joint Surgery (JBJS) looked at surgical site infections and hyperglycemia, the technical term for high blood glucose, or high blood sugar.

26 Jul 2012

Benefit of in-joint anesthesia queried in canine arthroscopy

Measurements of gait and lameness after arthroscopy in dogs show no evidence that either intra-articular bupivacaine or morphine provide an analgesic effect in the immediate postoperative period, despite bupivacaine having some effect on pain, report researchers.

25 Jul 2012

Constant pain after breast cancer surgery ‘more taxing’

Women who experience chronic pain after treatment for breast cancer are not significantly more anxious or depressed than women without pain, find researchers.

25 Jul 2012

Giving patients a new immune system can cure Crohn's disease

Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

25 Jul 2012

Latest polypill trial yields largest improvements yet

The results of the first trial to administer the polypill on the basis of age alone has shown the largest reductions in blood pressure and cholesterol level of any polypill trial to date, researchers report.

24 Jul 2012

Middle-aged female back pain sufferers commonly use CAM

Middle-aged women with back pain are commonly using both conventional and complementary and alternative medicine, Australian study findings show.

24 Jul 2012

Blood flow in blocked arteries to extremities improved by new angioplasty procedure

Patients with blocked arteries to their extremities, known as peripheral artery disease (PAD) or critical limb ischemia (CLI), may now find relief from lower leg pain and wounds caused by impaired leg artery circulation with the previously unproven therapy, percutaneous transluminal angioplasty (PTA).

24 Jul 2012

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck.

24 Jul 2012

Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.

24 Jul 2012

Study represents new use of bone marrow transplantation

24 Jul 2012

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.

24 Jul 2012

Study reveals 50% increased risk of urothelial and colorectal cancers in adulthood

Parents are increasingly conscious of the dangers of childhood obesity. There is a growing recognition of health problems associated with extra pounds, including the risk of diabetes, heart disease, and joint and muscle pain.

24 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Neural precursor cells suppress aggressive tumors

Neural precursor cells (NPC) in the young brain suppress certain brain tumors such as high-grade gliomas, especially glioblastoma (GBM), which are among the most common and most aggressive tumors.

23 Jul 2012

Once-daily Gralise significantly reduces pain intensity in PHN patients

Depomed, Inc. today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN).

23 Jul 2012

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

Chiasma, Inc., a privately held biopharma company, announced that it closed a $38.5 million equity financing co-led by new investor Abingworth and current investor MPM Capital that also included investments from existing shareholders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures and Fredric Price, Chiasma's Chairman & CEO.

23 Jul 2012

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012

FDA meeting confirms Orexo regulatory submission of OX219 NDA on track

A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.

23 Jul 2012

Chewing gum may relieve the pain of braces

Young adolescents and teens with fixed orthodontic appliances who chew gum report significantly less pain and impact of their braces than their peers who do not chew gum, report researchers from Sheffield in the UK.

23 Jul 2012